Renal calcium stones: Insights from the control of bone mineralization

Experimental Physiology

Volumn 93, Issue 1, 2008, Pages 43-49

  Moochhala, S H ^a   Sayer, J A ^a,b   Carr, G ^a   Simmons, N L ^a,b,c  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; PYROPHOSPHATE;

BONE MINERALIZATION; CALCIUM TRANSPORT; DISEASE COURSE; HUMAN; KIDNEY CALCIFICATION; KIDNEY COLLECTING TUBULE; KIDNEY CONCENTRATING CAPACITY; KNOCKOUT MOUSE; MOLECULAR BIOLOGY; NEPHROLITHIASIS; NONHUMAN; PREVENTION AND CONTROL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECURRENT DISEASE; REVIEW;

EID: 37349123855     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.040790     Document Type: Review

References (45)

1. Addison WN, Azari F, Sorensen ES, Kaartinen MT & McKee MD (2007). Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282, 15872 15883.
2. Baumann JM, Bisaz S, Felix R, Fleisch H, Ganz U & Russell RG (1977). The role of inhibitors and other factors in the pathogenesis of recurrent calcium-containing renal stones. Clin Sci Mol Med 53, 141 148.
3. Canales BK, Leonard SM, Singh JA, Orzano IM, Zimmermann B, Weiland D, Monga M & Krug HE (2006). Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 20, 542 546.
4. Carr G, Sayer JA & Simmons NL (2007). Expression and localisation of the pyrophosphate transporter, ANK, in murine kidney cells. Cell Physiol Biochem 20, 507 516.
5. Cebotaru V, Kaul S, Devuyst O, Cai H, Racusen L, Guggino WB & Guggino SE (2005). High citrate diet delays progression of renal insufficiency in the ClC-5 knockout mouse model of Dent's disease. Kidney Int 68, 642 652.
6. Costa-Bauza A, Barcelo C, Perello J & Grases F (2002). Synergism between the brushite and hydroxyapatite urinary crystallization inhibitors. Int Urol Nephrol 34, 447 451.
7. Costa-Bauza A, Isern B, Perello J, Sanchis P & Grases F (2005). Factors affecting the regrowth of renal stones in vitro: a contribution to the understanding of renal stone development. Scand J Urol Nephrol 39, 194 199.
8. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL & Grynpas M (2003). Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111, 607 616.
9. Evan A, Lingeman J, Coe FL & Worcester E (2006). Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69, 1313 1318.
10. Fleisch H & Bisaz S (1962). Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203, 671 675.
11. Goding JW, Grobben B & Slegers H (2003). Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/ phosphodiesterase family. Biochim Biophys Acta 1638, 1 19.
12. Grases F, Ramis M & Costa-Bauza A (2000). Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization. Comparison with the action of other polyphosphates. Urol Res 28, 136 140.
13. Gurley KA, Chen H, Guenther C, Nguyen ET, Rountree RB, Schoor M & Kingsley DM (2006a). Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res 21, 1238 1247.
14. Gurley KA, Reimer RJ & Kingsley DM (2006b). Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet 79, 1017 1029.
15. Harahap AR & Goding JW (1988). Distribution of the murine plasma cell antigen PC-1 in non-lymphoid tissues. J Immunol 141, 2317 2320.
16. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R & Millan JL (2004). Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164, 1199 1209.
17. Ho AM, Johnson MD & Kingsley DM (2000). Role of the mouse ank gene in control of tissue calcification and arthritis. Science 289, 265 270.
18. i increase depends on nucleotide release and subsequent purinergic signaling in the intact nephron. J Am Soc Nephrol 18, 2062 2070.
19. - channels gleaned from human genetic disease and mouse models. Annu Rev Physiol 67, 779 807.
20. Jung A, Bisaz S & Fleisch H (1973). The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11, 269 280.
21. 32P in dogs. Am J Physiol 218, 1757 1764.
22. Laminski NA, Meyers AM, Sonnekus MI & Smyth AE (1990). Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities. Nephron 56, 379 386.
23. Mahowald ML, Krug H & Taurog J (1988). Progressive ankylosis in mice. An animal model of spondylarthropathy. I. Clinical and radiographic findings. Arthritis Rheum 31, 1390 1399.
24. March JG, Simonet BM & Grases F (2001). Determination of pyrophosphate in renal calculi and urine by means of an enzymatic method. Clin Chim Acta 314, 187 194.
25. Nouwen EJ & De Broe ME (1994). Human intestinal versus tissue-nonspecific alkaline phosphatase as complementary urinary markers for the proximal tubule. Kidney Int Suppl 47, S43 S51.
26. Nurnberg P, Thiele H, Chandler D, Hohne W, Cunningham ML, Ritter H, Leschik G, Uhlmann K, Mischung C, Harrop K, Goldblatt J, Borochowitz ZU, Kotzot D, Westermann F, Mundlos S, Braun HS, Laing N & Tinschert S (2001). Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet 28, 37 41.
27. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, Dixey J, Gillet P, Loeuille D, McGrath R, Reginato A, Shiang R, Wright G, Netter P, Williams C & Kingsley DM (2002). Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 71, 933 940.
28. Qiu SR, Wierzbicki A, Orme CA, Cody AM, Hoyer JR, Nancollas GH, Zepeda S & De Yoreo JJ (2004). Molecular modulation of calcium oxalate crystallization by osteopontin and citrate. Proc Natl Acad Sci U S A 101, 1811 1815.
29. Rachow JW & Ryan LM (1988). Inorganic pyrophosphate metabolism in arthritis. Rheum Dis Clin North Am 14, 289 302.
30. Roberts NB, Dutton J, Helliwell T, Rothwell PJ & Kavanagh JP (1992). Pyrophosphate in synovial fluid and urine and its relationship to urinary risk factors for stone disease. Ann Clin Biochem 29, 529 534.
31. Russell RG (1976). Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 19 (Suppl. 3 465 478.
32. Russell RG, Bisaz S & Fleisch H (1976). The influence of orthophosphate on the renal handling of inorganic pyrophosphate in man and dog. Clin Sci Mol Med 51, 435 443.
33. Ryan LM (2001). The ank gene story. Arthritis Res 3, 77 79.
34. Sampson HW, Davis RW & Dufner DC (1991). Spondyloarthropathy in progressive ankylosis mice: ultrastructural features of the intervertebral disk. Acta Anat (Basel) 141, 36 41.
35. Sayer JA, Carr G & Simmons NL (2004). Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 106, 549 561.
36. Terkeltaub RA (2001). Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 281, C1 C11.
37. Timms AE, Zhang Y, Bradbury L, Wordsworth BP & Brown MA (2003). Investigation of the role of ANKH in ankylosing spondylitis. Arthritis Rheum 48, 2898 2902.
38. Tsui HW, Inman RD, Paterson AD, Reveille JD & Tsui FW (2005). ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 7, R513 R525.
39. Vekaria RM, Shirley DG, Sevigny J & Unwin RJ (2006a). Immunolocalization of ectonucleotidases along the rat nephron. Am J Physiol Renal Physiol 290, F550 F560.
40. Vekaria RM, Unwin RJ & Shirley DG (2006b). Intraluminal ATP concentrations in rat renal tubules. J Am Soc Nephrol 17, 1841 1847.
41. Verhulst A, Persy VP, Van Rompay AR, Verstrepen WA, Helbert MF & De Broe ME (2002). Osteopontin synthesis and localization along the human nephron. J Am Soc Nephrol 13, 1210 1218.
42. Verkoelen CF & Verhulst A (2007). Proposed mechanisms in renal tubular crystal retention. Kidney Int 72, 13 18.
43. Verstrepen WA, Persy VP, Verhulst A, Dauwe S & De Broe ME (2001). Renal osteopontin protein and mRNA upregulation during acute nephrotoxicity in the rat. Nephrol Dial Transplant 16, 712 724.
44. Whyte MP (1994). Hypophosphatasia and the role of alkaline phosphatase in skeletal mineralization. Endocr Rev 15, 439 461.
45. Wikström B, Danielson BG, Ljunghall S, McGuire M & Russell RGG (1983). Urinary pyrophosphate excretion in renal stone formers with normal and impaired renal acidification. World J Urol 1, 150 154.